Gene therapy prices have been rising
Selection of gene therapies approved by the US Food and Drug Administration since 2019. All are single-dose treatments.
| ZOLGENSMA | 2019 | 2,125,000 |
|---|---|---|
| HEMGENIX | 2022 | 3,500,000 |
| ZYNTEGLO | 2022 | 2,800,000 |
| SKYSONA | 2022 | 3,000,000 |
| ROCTAVIAN | 2023 | 2,900,000 |
| ELEVIDYS | 2023 | 3,200,000 |
| LYFGENIA | 2023 | 3,100,000 |
| CASGEVY | 2023 | 2,200,000 |
| LIBMELDY | 2024 | 4,250,000 |
